[1] 吴洪斌,陆益,陆国春.甲磺酸伊马替尼的不良反应及预防处理[J].中国新药杂志,2006,15(22):1923-1929. [2] 谢周涛,李德秀.甲磺酸伊马替尼不良反应的文献分析[J].医药导报,2011,30(7):963-964. [3] Zachry WM III,Doan QD,Clewell JD,et al. Case-control analysis of ambulance,emergency room,or inpatient hospital events for epilepsy and antiepileptic drug formulation changes[J]. Epilepsia,2009,50(3):493-500. [4] Rascati KL,Richards KM, Johnsrud MT,et al. Effects of antiepileptic drug substitutions on epileptic events requiring acute care[J]. Pharmacotherapy,2009,29(7):769-774. [5] Hansen RN,Campbell JD,Sullivan SD.Association between antiepileptic drug switching and epilepsy-related events[J]. Epilepsy Behav,2009,15(4):481-485. [6] 谢沐风,张启明,陈洁,等. 国外药政部门采用溶出曲线评价口固体制剂内在品质情况简介[J].中国药事,2008,22(3):257-261. [7] 谢沐风.解读“口服固体制剂仿制药一致性评价技术手段——多条溶出曲线”[J].中国医药工业杂志,2013,44(4):411-414. [8] 国家食品药品监督管理总局.普通口服固体制剂溶出度试验技术指导原则[EB/OL].(2015-02-05)[2017-08-27]. http://www.sfda.gov.cn/WS01/CL1757/114288.html. [9] 国家食品药品监督管理总局.甲磺酸伊马替尼片[S]. JX20040087. [10] 盛宝东,王雪琦,汪电雷,等.甲磺酸伊马替尼片溶出度检测方法的建立[J].安徽医药,2015,19(6):1078-1081. [11] 王淑华.甲磺酸伊马替尼片的开发[D].山东:山东大学硕士学位论文,2015. [12] FDA. Dissolution methods[EB/OL]. (2011-09-22)[2017-09-28].https://www.accessdata.fda.gov/scripts/cder/dissolution/dsp_SearchResults.cfm. [13] 张启明,谢沐风,宁保明,等.采用多条溶出曲线评价口服固体制剂的内在质量[J].中国医药工业杂志,2009,40(12):946-955. [14] Robertsen I,?sberg A,Inger? AO,et al. Use of generic tacrolimus in elderly renal transplant recipients[J]. Transplantation,2015,99(3):528-532. [15] Min SI,Ha J,Kim YS,et al. Therapeutic equivalence and pharmacokinetics of generic tacrolimus formulation in de novo kidney transplant patients[J]. Nephrol Dial Transplant,2013,28(12):3110-3119.
|